Pharma BD Deal Intelligence

Lineage Cell Therapeutics, Inc. / NeuroAirmid Therapeutics, Inc.

2026 · Acquisition/Merger · $58M · Complete

Lineage Cell Therapeutics acquired all outstanding shares of NeuroAirmid Therapeutics, making it a wholly owned subsidiary and adding hNSC-01 (renamed HUNT1), a clinical-stage pluripotent stem cell derived neural cell therapy for Huntington's Disease. In connection with the acquisition NeuroAirmid entered an amended and restated exclusive license with The Regents of the University of California for the program. At closing Lineage paid USD 2.4 million cash, issued 2.2 million common shares valued at USD 2.1 million, funded a USD 0.2 million sellers' representative expense fund and paid USD 1.7 million to satisfy NeuroAirmid third-party obligations, with up to USD 48 million in clinical and regulatory milestones. An ongoing trial plans to enroll up to 21 patients across five cohorts.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.

Key facts

Related deals

See the full interactive analysis, sources & comparables →